

Steffi Urbschat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8212207/publications.pdf>

Version: 2024-02-01

36
papers

772
citations

567281

15
h-index

526287

27
g-index

36
all docs

36
docs citations

36
times ranked

1010
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of MiRNA-181a2 on the Clinical Course of IDH1 Wild Type Glioblastoma. <i>Processes</i> , 2021, 9, 728.	2.8	1
2	CK2 Activity Mediates the Aggressive Molecular Signature of Glioblastoma Multiforme by Inducing Nerve/Glial Antigen (NG)2 Expression. <i>Cancers</i> , 2021, 13, 1678.	3.7	11
3	The Loss of 1p as a Reliable Marker of Progression in a Child with Aggressive Meningioma: A 16-Year Follow-Up Case Report. <i>Pediatric Neurosurgery</i> , 2020, 55, 418-425.	0.7	1
4	MiRNA-181d Expression Significantly Affects Treatment Responses to Carmustine Wafer Implantation. <i>Neurosurgery</i> , 2019, 85, 147-155.	1.1	10
5	Incidence, mortality and outcome of meningiomas: A population-based study from Germany. <i>Cancer Epidemiology</i> , 2019, 62, 101562.	1.9	90
6	The Influence of Distinct Regulatory miRNAs of the p15/p16/RB1/E2F Pathway on the Clinical Progression of Glioblastoma Multiforme. <i>World Neurosurgery</i> , 2019, 132, e900-e908.	1.3	7
7	miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme. <i>Acta Neurochirurgica</i> , 2019, 161, 2299-2309.	1.7	7
8	Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas. <i>Clinical Cancer Research</i> , 2019, 25, 5260-5270.	7.0	23
9	Deletions in the 17q chromosomal region and their influence on the clonal cytogenetic evolution of recurrent meningiomas. <i>Molecular Cytogenetics</i> , 2019, 12, 22.	0.9	9
10	Fluorescence imaging of meningioma cells with somatostatin receptor ligands: an in vitro study. <i>Acta Neurochirurgica</i> , 2019, 161, 1017-1024.	1.7	6
11	Combinational chromosomal aneuploidies and HPV status for prediction of head and neck squamous cell carcinoma prognosis in biopsies and cytological preparations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1129-1141.	2.5	3
12	Importance of biomarkers in glioblastomas patients receiving local BCNU wafer chemotherapy. <i>Molecular Cytogenetics</i> , 2017, 10, 16.	0.9	9
13	Promoter methylation of RB1, P15, P16, and MGMT and their impact on the clinical course of pilocytic astrocytomas. <i>Oncology Letters</i> , 2017, 15, 1600-1606.	1.8	9
14	Prognosis of meningiomas in the early 1970s and today. <i>Clinical Neurology and Neurosurgery</i> , 2016, 149, 98-103.	1.4	21
15	Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. <i>Oncotarget</i> , 2016, 7, 14551-14568.	1.8	36
16	Molecular Biological Determinations of Meningioma Progression and Recurrence. <i>PLoS ONE</i> , 2014, 9, e94987.	2.5	58
17	Establishment of a molecular cytogenetic analysis for native tumor tissue of meningiomas-suitable for clinical application. <i>Molecular Cytogenetics</i> , 2014, 7, 12.	0.9	12
18	New genetic findings in parotid gland pleomorphic adenomas. <i>Head and Neck</i> , 2013, 35, 1431-1438.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Confocal Laser Endomicroscopy in Neurosurgery: A New Technique with Much Potential. Minimally Invasive Surgery, 2013, 2013, 1-5.	0.5	12
20	Recurrence and Progression in Meningiomas. , 2012, , 191-201.		0
21	Clonal cytogenetic progression within intratumorally heterogeneous meningiomas predicts tumor recurrence. International Journal of Oncology, 2011, 39, 1601-8.	3.3	15
22	Glioblastoma Patients: p15 Methylation as a Prognostic Factor. , 2011, , 399-404.		0
23	CORRESPONDENCE OF TUMOR LOCALIZATION WITH TUMOR RECURRENCE AND CYTOGENETIC PROGRESSION IN MENINGIOMAS. Neurosurgery, 2008, 62, 61-70.	1.1	71
24	Application of oncogenetic trees mixtures as a biostatistical model of the clonal cytogenetic evolution of meningiomas. International Journal of Cancer, 2007, 121, 1473-1480.	5.1	44
25	Comprehensive genomic analysis identifiesMDM2 andAURKA as novel amplified genes in juvenile angiofibromas. Head and Neck, 2007, 29, 479-487.	2.0	16
26	Cytogenetic Relationship between Spinal Meningiomas and Their Recurrences. Skull Base, 2007, 17, .	0.4	0
27	Cytogenetic and molecular cytogenetic characterization of the stable ovarian carcinoma cell line (OvBH-1). Cancer Genetics and Cytogenetics, 2006, 164, 10-15.	1.0	1
28	Genetic heterogeneity of the MYC oncogene in advanced juvenile angiofibromas. Cancer Genetics and Cytogenetics, 2006, 164, 25-31.	1.0	27
29	Patients with High-Grade Gliomas Harboring Deletions of Chromosomes 9p and 10q Benefit from Temozolomide Treatment. Neoplasia, 2005, 7, 883-893.	5.3	55
30	p53 and Her-2/neu in juvenile angiofibromas. Oncology Reports, 2005, 13, 453-7.	2.6	20
31	New aspects of pathogenesis of juvenile angiofibroma. British Journal of Hospital Medicine, 2004, 65, 269-273.	0.2	28
32	Numerical sex chromosome aberrations in juvenile angiofibromas: genetic evidence for an androgen-dependent tumor?. Oncology Reports, 2003, 10, 1251-5.	2.6	28
33	First Evidence of Genetic Imbalances in Angiofibromas. Laryngoscope, 2002, 112, 397-401.	2.0	29
34	Simultaneous Multicolor-FISH and Immunocyto-chemical Analysis of Fresh Tumor Material. , 2002, , 432-441.		0
35	Comparative Genomic Hybridization Reveals Recurrent Enhancements on Chromosome 20 and in One Case Combined Amplification Sites on 15q24q26 and 20p11p12 in Glioblastomas. Cancer Genetics and Cytogenetics, 2000, 121, 124-127.	1.0	18
36	Evidence of Focal Genetic Microheterogeneity in Glioblastoma Multiforme by Area-Specific CGH on Microdissected Tumor Cells. Journal of Neuropathology and Experimental Neurology, 1999, 58, 993-999.	1.7	89